Stranger than fiction.

Gold funds rise, but financials fall.

Shares collapse 39% as the Fed bails the company out.

Most funds in the commodity space enjoyed strong gains in the three months ended Feb. 29.

Amgen and Genentech bring down biotech stocks.

Bear Stearns dragged down financial stocks with it.

The beleaguered investment bank’s 85-year run as an independent company could be in doubt.

This week, how to enter and exit trades, plus, finding the VIX.

On Tuesday, there was a huge, anomalous trade in Bear’s March 30 puts.

Strength in agricultural products, emerging markets and productivity gains offset U.S. weakness.

Cramer says he likes the stock’s high yield.